Loading
Danimer Scientific, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HENDRIX RICHARD J, was filed 28 Nov 2023.
Danimer Scientific, Inc.: what insiders have been doing
Every trade that managers of Danimer Scientific, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Chemicals & Materials sector. Nothing new has been filed by managers of Danimer Scientific, Inc. in twelve months, the latest record being from 10 February 2025.
Since 2020, the database holds 4 purchases and 32 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
129
Thresholds
n/a
Buy Volume
€40M
4 ops. · all time
Sell Volume
€3M
32 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Net income-US$133.9M
Last declaration on 10 February 2025
Declarations129 total
301 shares@ US$1.180.5% of flowClass A Common StockSEC:0000950170-25-017112:1
859 sharesClass A Common StockSEC:0000950170-25-017112:0
646 shares0Class A Common StockSEC:0000950170-25-007293:0
23,256 shares0Class A Common StockSEC:0000950170-24-068808:0
16,611 shares0Class A Common StockSEC:0000950170-24-068816:0
18,272 shares0Class A Common StockSEC:0000950170-24-068817:0
18,272 shares0Class A Common StockSEC:0000950170-24-068810:0
16,611 shares0Class A Common StockSEC:0000950170-24-068812:0
16,611 shares0Class A Common StockSEC:0000950170-24-068814:0
26,578 shares0Class A Common StockSEC:0000950170-24-068813:0
16,611 shares0Class A Common StockSEC:0000950170-24-068811:0
12,076 shares@ US$0.6611.4% of flowClass A Common StockSEC:0001209191-24-002996:1
34,364 sharesClass A Common StockSEC:0001209191-24-002996:0
28,358 shares@ US$1.025.5% of flowClass A Common StockSEC:0001209191-24-000192:0
18,926 shares@ US$1.021.9% of flowClass A Common StockSEC:0001209191-24-000198:0
18,926 shares@ US$1.026.9% of flowClass A Common StockSEC:0001209191-24-000194:0
50,000 shares@ US$0.92960.1% of flowClass A Common StockSEC:0001209191-23-056829:1
Canonical exit: 26 Feb 2024 (T+90)
50,000 shares@ US$0.9383100.0% of flowClass A Common StockSEC:0001209191-23-056829:0
Canonical exit: 26 Feb 2024 (T+90)
10,000 shares@ US$2.7392.7% of flowClass A Common StockSEC:0001209191-23-038501:0
10,000 shares@ US$3.3813.4% of flowClass A Common StockSEC:0001209191-23-030249:0
441 sharesClass A Common StockSEC:0001209191-23-029615:0
27,986 sharesClass A Common StockSEC:0001209191-23-029171:1
545 sharesClass A Common StockSEC:0001209191-23-029171:2
199 sharesClass A Common StockSEC:0001209191-23-029176:0
39,333 sharesClass A Common StockSEC:0001209191-23-029172:0
25 of 129 declarations
About Danimer Scientific, Inc.
Danimer Scientific, Inc. (ticker: DNMR) is a U.S.-listed company traded on the NASDAQ in the United States. For French-speaking investors, it fits best within the specialty chemicals/materials universe, with an environmental and sustainability angle. The company is headquartered in Bainbridge, Georgia, United States, where it also maintains key operating facilities and R&D capabilities.
Danimer’s roots go back to a biotechnology and materials platform built around intellectual property acquired from Procter & Gamble in 2007. Over time, the company evolved into a developer and producer of polyhydroxyalkanoates (PHAs), a family of biodegradable biopolymers used as an alternative to conventional petroleum-based plastics. Its flagship commercial platform is Nodax®, a proprietary PHA resin family designed for a range of end uses, including packaging, food-service items, and other applications where performance, processability, and end-of-life biodegradability matter. Danimer also emphasizes custom formulation work, research and development services, and toll manufacturing / contract production capabilities.
Read moreShow less
From a business-model perspective, Danimer is differentiated by materials science rather than commodity scale. The company’s competitive position is built on proprietary know-how, patent protection, product performance, and the ability to work with large consumer-goods customers that are trying to reduce plastic waste. Management has positioned the company around the commercialization of biobased materials that can biodegrade in specific conditions, which gives DNMR exposure to regulatory, sustainability, and packaging-trend themes. At the same time, that positioning typically requires long qualification cycles, customer testing, and scale-up execution, making the investment case more dependent on operational delivery than on simple market-share gains.
Geographically, the company remains primarily U.S.-based, but its commercial ambitions are broader, with relationships and development work tied to multinational customers and the potential for international demand. Danimer has highlighted a meaningful patent portfolio and a history of collaboration with major global brands, reinforcing its technology credentials while also underscoring the long lead time required to convert innovation into recurring revenue.
A major recent event is the company’s announced acquisition by Teknor Apex in 2025, which is strategically important and may materially affect the company’s future corporate profile and public-market status. For equity analysis, DNMR should therefore be viewed as a biopolymers and sustainable materials company with a strong technology narrative, but one that has also been shaped by restructuring, funding pressure, and sector consolidation. Insider Form 4 filings with the SEC remain relevant as an additional governance and sentiment indicator.
